Compare Eli Lilly And Co (LLY) vs TeraWulf Inc (WULF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs TeraWulf Inc — how do they compare? Eli Lilly And Co trades at $1,213.64 (market cap $1.08T), while TeraWulf Inc trades at $17.05 (market cap $8.35B). The key difference: Eli Lilly And Co is far larger — about 129.3× TeraWulf Inc's market cap, and Eli Lilly And Co pays a 0.57% dividend while TeraWulf Inc pays none. Which is the better fit depends on your goals.
| LLY | WULF | |
|---|---|---|
Market Cap | $1.08T | $8.35B |
Sector | Health | Technology |
52-Week High | $1.24K | $28.98 |
52-Week Low | $639.43 | $5.24 |
Enterprise Value | $1.13T | $10.97B |
Dividend Yield | 0.57% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,221.21, down 0.84% today, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The stock shows technical strength with bullish moving averages and support at $1,207, while fundamentals reveal exceptional profitability with 33.53% net margins and 48% revenue growth in Q2 2026. Recent news highlights the company's aggressive protection of its obesity drug pipeline against black market sales.
LLY presents a compelling growth story with dominant market positioning in weight-loss drugs and strong analyst support (73% buy ratings). Key risks include regulatory scrutiny and competitive pressures, but the company's raised guidance and pipeline advancements support continued upside toward the $1,380 consensus target.
WULF stock trades at $17.69, up 9.2% on the day amid a broader rally in AI infrastructure stocks. The technical picture is bearish with key support at $16 and resistance at $18. Fundamentally, the company reported a Q2 2026 net loss of $1.94 per share, missing estimates, while revenue trends are stable. Despite negative profitability metrics, analyst sentiment remains unanimously bullish with a $38.00 consensus price target, driven by expansion in high-performance computing capacity.
The outlook hinges on execution of its HPC growth strategy, but significant risks include persistent losses, high capital expenditure, and exposure to regulatory shifts. The stock offers high upside if operational targets are met, yet carries substantial volatility and execution risk for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About TeraWulf Inc
TeraWulf develops, owns, and operates fully integrated digital infrastructure powered by predominantly zero-carbon energy. It utilizes a hybrid business model that combines industrial-scale Bitcoin mining with high-performance computing (HPC) and AI hosting, leveraging sustainable power sources like nuclear and hydroelectric to deliver low-cost, energy-efficient data center solutions.
Read more on WULF →
